Article
[Hypomethylation and multiple sclerosis, the susceptibility factor?].
Neurologia (Barcelona, Spain) - 1 Mar 2002
Cara Terribas C J, González Guijarro L
Abstract excerpt
BACKGROUND: Azathioprine, off-label used long time ago to treat multiple sclerosis (MS) patients, has recently received approval from the Spanish Medicine Agency (Agencia Española del Medicamento) in relapsing-remitting (RR) forms of this condition. Clinical efficacy of azathioprine is due to the enzymatic conversion to 6-thioguanine (the active metabolite). The key enzyme in this process is thio purine methyl...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
